+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemophilia A and B - Epidemiology Forecast to 2030

  • PDF Icon

    Report

  • 54 Pages
  • October 2021
  • Region: Global
  • GlobalData
  • ID: 5464469
Description Jump to:
Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation because of deficiencies in the production or function of coagulation factor VIII in hemophilia A or factor IX in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency to bleed in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2021; Mayo Clinic, 2021). According to the World Federation of Hemophilia (WFH), hemophilia is rare. About 1 in 10,000 people are born with hemophilia A and about 1 in 50,000 people are born with hemophilia B (WFH, 2013). According to the WFH, only 4% of hemophilia A cases and 6% of hemophilia B cases are in women (WFH, 2020).

In the 8MM, the diagnosed prevalent cases of hemophilia A and hemophilia B are expected to increase from 73,437 cases in 2020 to 82,128 cases in 2030, at an Annual Growth Rate (AGR) of 1.18%. In 2030, China will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B in the 8MM, with 23,688 diagnosed prevalent cases, whereas Spain will have the fewest diagnosed prevalent cases with 2,975 cases. In the 8MM, the diagnosed prevalent cases of acquired hemophilia is expected to increase from 2,175 cases in 2020 to 2,210 cases in 2030, at an AGR of 0.16%. The analyst epidemiologists attribute the increase in the diagnosed prevalent cases of hemophilia A and hemophilia B to better diagnosis and population dynamics in each market.

Scope


  • This report provides an overview of the risk factors, comorbidities, and the global and historical trends for hemophilia A and hemophilia B in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). The report provides a 10-year epidemiological forecast of the diagnosed prevalent cases of hemophilia A and hemophilia B. In this analysis, hemophilia is grouped into the groups: Hemophilia A (ICD-10 code = D66), hemophilia B (ICD-10 code = D67), hemophilia A and B, and acquired hemophilia (ICD-10 code = D68.311).
  • The report provides a 10-year epidemiological forecast of the diagnosed prevalent cases of each of the four groups. The diagnosed prevalent cases of hemophilia A and hemophilia B groups are further segmented by severity (mild, moderate, and severe) and inhibitor status. In addition, the diagnosed prevalent cases of hemophilia A and hemophilia B were further segmented by severity (mild, moderate, and severe), inhibitor status, severity among inhibitors, prophylaxis, and on-demand treatment.
  • The hemophilia A and B epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy


The hemophilia A and B epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B market.
  • Quantify patient populations in the global hemophilia A and B market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for hemophilia A and B therapeutics in each of the markets covered.
  • Understand magnitude of hemophilia A and B by severity, inhibitors, severity among inhibitors, and type of treatment (prophylaxis and on-demand).

Table of Contents

1 Hemophilia A and B: Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 8MM Forecast Methodology
2.4.1 Sources
2.4.2 Sources Not Used
2.4.3 Forecast Assumptions and Methods
2.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
2.4.6 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
2.4.7 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.4.8 Types of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.4.9 Diagnosed Prevalent Cases of Acquired Hemophilia
2.5 Epidemiological Forecast for Hemophilia A (2020-2030)
2.5.1 Diagnosed Prevalent Cases of Hemophilia A
2.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
2.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
2.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
2.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
2.6 Epidemiological Forecast for Hemophilia B (2020-2030)
2.6.1 Diagnosed Prevalent Cases of Hemophilia B
2.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
2.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia B
2.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
2.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
2.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2020-2030)
2.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
2.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
2.7.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.7 Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
2.7.8 Diagnosed Prevalent Cases of Acquired Hemophilia
2.8 Discussion
2.8.1 Epidemiological Forecast Insight
2.8.2 COVID-19 Impact
2.8.3 Limitations of the Analysis
2.8.4 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
Contact Us
List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Relationship of Bleeding Severity with Clotting Factor Level.
Table 4: Comorbidities for Hemophilia
List of Figures
Figure 1: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, N, All Ages, 2020 and 2030
Figure 2: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, Both Sexes, N, All Ages, 2020 and 2030
Figure 3: 8MM, Diagnosed Prevalence of Hemophilia A (%), Both Sexes, All Ages
Figure 4: 8MM, Diagnosed Prevalence of Hemophilia B (%), Both Sexes, All Ages
Figure 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Inhibitors
Figure 8: 8MM, Sources Used to Forecast the Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 9: 8MM, Sources Used to Forecast the Types of Treatment Among Hemophilia A and Hemophilia B Patients
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acquired Hemophilia
Figure 11: 8MM, Diagnosed Prevalent Cases of Hemophilia A, N, Both Sexes, All Ages, 2020
Figure 12: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Age, N, Both Sexes
Figure 13: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Sex, N, All Ages, 2020
Figure 14: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, N, Both Sexes, All Ages, 2020
Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, N, Both Sexes, All Ages, 2020
Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia B, N, Both Sexes, All Ages, 2020
Figure 17: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Age, N, Both Sexes
Figure 18: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Sex, N, All Ages, 2020
Figure 19: 8MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, N, Both Sexes, All Ages, 2020
Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, N, Both Sexes, All Ages, 2020
Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, N, Both Sexes, All Ages, 2020
Figure 22: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Age, N, Both Sexes, 2020
Figure 23: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex, N, All Ages, 2020
Figure 24: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, N, Both Sexes, All Ages, 2020
Figure 25: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, N, Both Sexes, All Ages, 2020
Figure 26: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020
Figure 27: 8MM, Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020
Figure 28: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, N, Both Sexes, All Ages, 2020

Related Topics

Related Reports

Hemophilia B - Pipeline Insight, 2024 - Product Image

Hemophilia B - Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Hemophilia A Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast 2018-2028 - Product Image

Hemophilia A Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast 2018-2028

  • Report
  • 178 Pages
  • Global
From
Hemophilia - Pipeline Insight, 2024 - Product Image

Hemophilia - Pipeline Insight, 2024

  • Drug Pipelines
  • 250 Pages
  • Global
From
Global Hemophilia Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Type (Hemophilia A, Hemophilia B), By Treatment Type (Prophylaxis, On-demand, and Cure), By Therapy, By Regional Outlook and Forecast, 2023 - 2030 - Product Image

Global Hemophilia Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Type (Hemophilia A, Hemophilia B), By Treatment Type (Prophylaxis, On-demand, and Cure), By Therapy, By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • 311 Pages
  • Global
From
Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2024-2028) - Product Image

Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)

  • Report
  • 102 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.